Michael Horberg

Michael Horberg, MD, MAS, FACP, FIDSA

Associate Medical Director of Research, Medical Education, Community Health, Medicaid, HIV & STD, Genetics, Transgender Health, Infection Prevention and Control

Executive Director, Mid-Atlantic Permanente Research Institute
Director HIV/AIDS and STD, Kaiser Permanente and Care Management Institute

Michael.Horberg@kp.org

Education:

MD, Boston University School of Medicine
MAS, University of California, San Francisco
BA, Boston University
Residency, Categorical Internal Medicine, Michael Reese Hospital/University of Chicago

Academic Affliations:

Professor of Medicine, Kaiser Permanente School of Medicine

Professional Affliations:

Chair, Kaiser Permanente National Research Council
Chair, AHIP/CMS HIV and Hepatitis C Quality Measures Working Group
Governing Board Member, Health Care Systems Research Network
Past Chair, HIV Medicine Association
Past President, Gay and Lesbian Medical Association
Fellow, American College of Physicians
Fellow, Infectious Disease Society of America
Member, AcademyHealth

Michael Alan Horberg, MD, MAS, FACP, FIDSA is Associate Medical Director for Kaiser Permanente Mid-Atlantic Permanente Medical Group (MAPMG).  In that role, he has responsibilities for Research, Medical Education, Community Health, Medicaid, Genetics, HIV and STD, Transgender Health and Infection Control and Prevention. He serves as the Executive Director of the Mid-Atlantic Permanente Research Institute (MAPRI).  As Executive Director, Dr. Horberg is responsible for all research activities in Kaiser Permanente Mid-Atlantic States (KPMAS).  As Associate Medical Director for Medical Education, he is the Designated Institutional Official for KPMAS.  He serves as the medical director for KPMAS Community Health, and is the Medicaid leader for MAPMG, including Chief Medical Officer for KPMAS in Maryland Medicaid, as well as helping lead clinical operational efforts in both Maryland and Virginia Medicaid, and serving on the KPMAS Medicaid Executive Committee. Michael leads HIV, STD, Infection Prevention, and transgender health care efforts in the region, and HIV and STD care program-wide for Kaiser Permanente.  This year, he is leading the opening of Pride Medical and KPMAS’ Gender Pathways programs and clinics. Dr. Horberg leads the Medical Genetics and Genomics strategy for MAPMG and is Executive Sponsor for KPMAS’ Commission on Cancer Accreditation and National Surgical Quality Improvement Program.

Dr. Horberg serves as director of HIV/AIDS program-wide for Kaiser Permanente and as Clinical Lead for HIV/AIDS and STDs for the Care Management Institute.  Under President Obama, Dr. Horberg has served on the Presidential Advisory Council on HIV/AIDS, having co-chaired the Access to Care and Improved Outcomes Committee.  Dr. Horberg is a Fellow of the American College of Physicians and the Infectious Disease Society of America (IDSA).  He is Past-Chair of the Board of Directors of the HIV Medicine Association of IDSA.  He has served on the IDSA Quality Performance Committee, and presently co-chairs the IDSA Primary Care Guideline Committee. Dr. Horberg has served as a commissioner on the State of Maryland Natalie M. LaPrade Medical Cannabis Commission.  He is past-president of the national Gay and Lesbian Medical Association.

In his role as Executive Director of MAPRI, Dr. Horberg leads a department of both clinical and data research with over sixty team members.  His HIV research interests are health service outcomes for HIV-infected patients (including HIV quality measures and care improvement, and determinants of optimized multidisciplinary care for maximized HIV outcomes), medication adherence issues in these patients, and epidemiology of the disease.  Dr. Horberg serves as the MAPRI and national principal investigator for the Kaiser Permanente Research Bank (national genomics initiative).  Other research interests include other sexually transmitted diseases and hepatitis.  Dr. Horberg has published over 150 manuscripts and delivered over one hundred presentations at scientific meetings; all are in peer-reviewed literature or conferences.  He has chaired multiple Expert Panels on HIV-related provider performance measures (including ones sponsored by CMS, NCQA, and IDSA), and has served on NIH and CDC peer-review panels.

A Chicagoan by birth, Dr. Horberg attended Boston University Medical School, and received his Master of Advanced Studies, from University of California San Francisco.  He is a resident of the District of Columbia with his husband Chip and their pet poodle Grant.

Research Interests:

HIV/AIDS:
  • Models of Care
  • HIV Care and Outcomes Quality Metrics
  • Registry Development
  • Pharmaceutical Safety and Comparative Effectiveness
Sexually Transmitted Disease:
  • Gay/Lesbian Health and STI risk
  • Syphilis
Hepatitis:
  • Registry Development
  • Hepatitis Care Quality Metrics

For a full list of publications, please see Dr. Horberg’s Curriculum Vitae.

  1. Nadison M, Flamm L, Roberts A, Staton T, Wiener L, Locke J, Bullock E, Loftus B, Carpenter C, Sadler M, Horberg M. “Kaiser Permanente’s Good Health & Great Hair Program: Partnering with Barbershops and Beauty Salons to Advance Health Equity in West Baltimore, Maryland.” Journal of Public Health Management Practice. 2021; e-pub ahead of print.
  2. Kasaie P, Stewart C, Humes E, Gerace L, Zhang J, Silverberg MJ, Horberg M, Rebeiro PF, Hyle E, Lima V, Wong C, Gill MJ, Gebo K, Moore, Kitahata M, Althoff K. “Projecting the Age-Distribution of Men who have Sex with Men Receiving HIV Treatment in the United States.” Annals of Epidemiology. 2021; October 7:S1047-2797(21)00281-7.
  3. Finch A, Crowell A, Chang YC, Parameshwarappa P, Martinez J, Horberg M. “A Comparison of Attnetional Neural Network Architectures for Modeling with Electronic Medical Records.” JAMIA Open . 021; August 12, 4(3): ooab064.
  4. Davy-Mendez T, Napravnik S, Eron J, Cole S, Van Duin D, Wohl D, Gebo K, Moore R, Althoff K, Poteat T, Gill MJ, Horberg M, Silverberg M, Nanditha N, Thorne J, Berry S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. “Current and Past Immunodeficiiency are Associated with Higher Hospitalization Rates among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years.” Journal Infectious Diseases. 2021; 224(4): 657- 666.
  5. Simon G, Bindman A, Dreyer N, Platt R, Watanabe J, Horberg M, Hernandez A, Califf R. “When Can We Trust Real-World Data to Evaluate New Medical Treatments?” Clinical Pharmacology & Therapeutics. 2021; e-pub ahead of print.
  6. Simon G, Platt R, Watanabe J, Bindman A, London A, Horberg M, Hernandez A, Califf R. “When Can we Rely on Real-World Evidence to Evaluate New Medical Treatments?” Clinical Pharmacology & Therapeutics. 2021; e-pub ahead of print.
  7. Edwards J, cole S, Breger T, Rudolph J, Filiatreau L, Buchacz K, Humes E, Rebeiro P, D’Souza G, Gill MJ, Silverberg M, Mathews C, Horberg M, Thorne J, Hall HI, Justice A, Marconi V, Lima V, Bosch R, Sterling T, Althoff K, Moore R, Saag M, Eron J. “Mortality among Persons Entering HIV Care Compared with the General US Population.” Annals of Internal Medicine. 2021; 174(4): 1197-1206.
  8. McGinnis K, Justice A, Moore R, Sivlerberg M, Althoff K, Karris M, Lima V, Crane H, Horberg M, Klein M, Gange S, Gebo K, Mayor A, Tate J, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA and Veterans Aging Cohort Study. ““Discrimination and
    Calibration of the VACS Index 2.0 for Predicting Mortality among People with HIV in North America.” Clinical Infectious Diseases. 2021; e-pub ahead of print
  9. Monroe A, Levy M, Greenberg A, Keruly J, Moore R, Horberg M, Kulie P, Mohanraj B, Kumar P, Castel A, on behalf of the DC Cohort Executive Committee. “Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts.” Open Forum Infectious Diseases. 2021; July 27:8(8):ofab388.
  10. Rahman V, Horberg M, Hu H, Vupputuri S. “Implementation of a Plant-Based Nurtrition Program in a Large Integrated Health Care System: Results of a Pilot Program.” J Primary Care and Community Health. 2021; January-December 12: 21501327211053198.
  11. Horberg MA, Nassery N, (co-lead author), Rubenstein KB, Certa JM, Watson E, Somasundaram B, Shamim E, Townsend JL, Galiatsatos P, Pitts SI, Hassoon A, Newman-Toker DE. ““Rate of sepsis hospitalizations after misdiagnosis in adult emergency department patients: A look-forward analysis with administrative claims data using SPADE methodology in an integrated health system.” Diagnosis (Berlin). 2021; e-pub ahead of print.
  12. Kim NH, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Rajender Reddy K, Lim JK, Silverberg MJ, Mayor AM, Horberg MA , Cachay ER, Kirk GD, Sun J, Hull M, John Gill M, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Lo Re V 3rd, The North American Aids Cohort Collaboration On Research F, Of IeDEA. ““Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus-Coinfected Persons in North America.” Hepatology. 2021 Mar 29 (e-pub ahead of print) .
  13. Satre DD, Levine-Hall T, Sterling SA, Young-Wolff KC, Lam JO, Alexeeff S, Hojilla JC, Williams A, Justice AC, Sterne J, Cavassini M, Bryant KJ, Williams EC, Horberg MA, Volberding P, Weisner C, Silverberg MJ.Satre DD, et al. “The relationship of smoking and unhealthy alcohol use to the HIV care continuum among people with HIV in an integrated health care system.” Drug Alcohol Depend. 2021 Feb 1;219:108481.
  14. Lee J, Humes E, Hogan B, Buchacz K, Eron J, Gill MJ, Sterling T, Rebeiro P, Dias Lima V, Mayor A, Silverberg M, Horberg M, Moore R, Althoff K, for the North American AIDS cohort Collaboration on Research and Design. “CD4 Count at Entry into HIV Care and at Antiretroviral Therapy Prescription in the US, 2005-2018.” Clinical Infectious Diseases. 2020; e-pub ahead of print.
  1. HIV Status and Incidence and Outcomes of Heart Failure
    Goal: The overall purpose of this study is to work with our clinical and policy leaders in HIV and CHF care to quantify the risk of congestive heart failure (CHF) among HIV-infected patients, which antiretroviral therapy medications have increased risk for CHF, and which may be protective, as well as develop care patterns for CHF among our HIV-infected patients.
    Funder: National Heart, Lung, and Blood Institute
    Role: Co-Investigator
  2. The DC Cohort: A Longitudinal Population-Based Cohort Study of People Living With HIV in Washington, DC
    Goal: The goals of this study are 1) enhance the Cohort database to incorporate new data sources to comprehensively describe and monitor HIV and co-occurring conditions; 2) expand the use of the existing DC Cohort Clinical Dashboard to monitor HIV care outcomes as well as key indicators related to ending the HIV epidemic; and 3) use the Cohort as a platform from which to develop pioneering interventions to improve the quality of care of PLWH.
    Funder: National Institute of Allergy and Infectious Disease/The George Washington University
    Role: Co-Investigator
  3. Kaiser Permanente Research Bank
    Goal: In this study, KP Research Bank aims to recruit 280K members total across all KP regions to increase the overall Research Bank collection to 500K. Members will be consented to provide a biospecimen and complete a survey. This region will participate in the recruitment and other Research Bank-related efforts, including scientific, strategic and operational.
    Funder: Kaiser Permanente Mid-Atlantic Community Benefits
    Role:
    Principal Investigator
  4. North American AIDS Cohorts Collaboration on Research and Design (NA-ACCORD)
    Goal:
    This is the North America response to IeDEA, and for which Kaiser Permanente Northern California participates. It is a collaborative cohort compendium and analysis for purposes of achieving sufficient power to address issues that could not be adequately addressed by single cohorts.
    Funder:
    National Institute of Allergy and Infectious Diseases
    Role: Site Principal Investigator
  5. CIVETS of the North American AIDS Cohorts Collaboration on Research and Design (NA-ACCORD)
    Goal: The purpose of this study is for the existing NA-ACCORD collaborators to share data collection instruments, algorithms for identifying COVID-19 disease, and analytic approaches to expedite answers to urgent questions in multiple data sources.
    Funder: National Institute of Allergy and Infectious Diseases
    Role: Co-Investigator
  6. Kaiser Permanente HIV Quality Improvement and Performance Program
    Goal: We seek to determine quantitative measures of HIV care and outcomes in Kaiser Permanente, which has never been done on a systematic basis in a managed care organization previously.  We seek to then initiate quality improvement programs where we determine there are opportunities for improvement.
    Funder: Care Management Institute/The Permanente Federation/Kaiser Health Plans
    Role: Principal Investigator
  7. Implementing Computerized Substance Use and Depression Screening and Evidence-Based Treatments in an HIV Primary Care Population
    Goal: The purpose of the overall study is to address the important topic of alcohol, smoking and other substance use and comorbidity screening and treatment among HIV-impacted patients. This study represents an important next step in the evolution of our top-quality HIV care in the context of an aging HIV patient population and has important implications beyond the Kaiser Permanente system.
    Funder: National Institute on Alcohol, Abuse and Alcoholism
    Role: Site Principal Investigator
  8. HIV Infection, Use of Tenofovir and Other Antiretrovirals, and Risk of Fatal and Non-Fatal Comorbidities: Cohort study in Kaiser Permanente
    Goal: The purpose of the overall study is to primarily compare the incidence rate of fatal and non-fatal comorbidities in HIV patients with incidence rates among matched HIV-uninfected controls, and HIV-uninfected individuals prescribed PrEP.
    Funder: Gilead, Inc.
    Role: Co-Principal Investigator
  9. COMpAAAS Tripartite: ART-CC, KP, and VA
    Goal: The purpose of the overall study is to participate in a scientific collaboration across three grant partners to assemble data sets, including electronic health record data.  Partners will interpret and disseminate results of the study through conference abstracts and manuscripts.
    Funder: National Institute of Health
    Role: Site Principal Investigator
  10. National Diagnostic Performance Dashboard to Measure and Track Diagnostic Error Using Big Data
    Goal: The goal of this study is to measure and track “missed diagnoses” of sepsis, stroke, and myocardial infarction and display information in ways that can be acted upon to reduce morbidity and mortality.
    Funder: Gordon & Betty Moore Foundation
    Role: Co-Investigator
  11. KPMAS HIV Registry
    Goal:
    Develop the HIV registry that closely aligns with the other KP regions’ case definitions. This registry will be used to identify populations for potential research studies, clinical trials, and clinical applications as required.
    Funder:
    Kaiser Permanente Mid-Atlantic Community Benefits
    Role:
    Principal Investigator
  12. KPMAS Hepatitis Registries
    Goal:
    Development of the hepatitis B and C registries are critical to ongoing research efforts for KPMA. The hepatitis C registry case finding and registry population is ongoing, with development of hepatitis B and cirrhosis registries next. Both epidemiologic and clinical applications are anticipated.
    Funder:
    Kaiser Permanente Mid-Atlantic Community Benefits
    Role:
    Principal Investigator
  13. KPMAS Sickle Cell Disease Registry
    Goal:
    Develop a sickle cell disease registry that closely aligns with the other KP regions’ case definitions. The registry will be used to facilitate future IRB-approved research based on known cases within the registry, to improve care, and to enhance clinical decision making.
    Funder: Kaiser Permanente Mid-Atlantic Community Benefits
    Role:
    Principal Investigator